GENinCode Lifts Fundraise to £4.7m After Strong Investor Demand

An update from GENinCode UK Ltd. ( (GB:GENI) ) is now available.

GENinCode Plc has expanded its recent fundraising following additional investor interest, agreeing an extra subscription for 58 million new ordinary shares at 1 pence each to raise a further £580,000. Subject to shareholder approval of the relevant resolutions at a forthcoming general meeting, the company will have raised approximately £4.7 million in gross proceeds in aggregate, strengthening its cash runway as it works to provide the US Food and Drug Administration with required updates for the De Novo application of its CARDIO inCode-Score test and supporting ongoing operations in the competitive predictive genetics sector.

The most recent analyst rating on (GB:GENI) stock is a Hold with a £1.00 price target. To see the full list of analyst forecasts on GENinCode UK Ltd. stock, see the GB:GENI Stock Forecast page.

Spark’s Take on GB:GENI Stock

According to Spark, TipRanks’ AI Analyst, GB:GENI is a Underperform.

The score is primarily weighed down by weak financial performance (persistent losses, negative operating cash flow, and declining equity). Technicals reinforce the risk with a clear downtrend and negative MACD, while valuation provides limited support due to a negative P/E and no dividend data.

To see Spark’s full report on GB:GENI stock, click here.

More about GENinCode UK Ltd.

GENinCode Plc, listed on AIM, is a predictive genetics company focused on preventing cardiovascular disease and ovarian cancer. It develops and commercialises genetic testing solutions, including its CARDIO inCode-Score test, with a market focus on improving early risk detection and prevention in major chronic diseases.

Average Trading Volume: 2,142,427

Technical Sentiment Signal: Sell

Current Market Cap: £3.51M

For detailed information about GENI stock, go to TipRanks’ Stock Analysis page.